Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus salivarius BP121
- Development stage
- Preclinical
- Lead developer
- GC Wellbeing
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
GCWB108 is a probiotic strain of *Lactobacillus salivarius* (specifically *Lactobacillus salivarius* BP121) being developed by GC Green Cross Wellbeing for kidney health. It is designed to improve kidney function, reduce inflammation of kidney tissue, and decrease the production of uremic toxins such as indoxyl sulfate (IS) and p-cresol sulfate (PCS) in the blood. Preclinical studies have shown that GCWB108 can protect against cisplatin-induced acute kidney injury (AKI) by stabilizing intestinal barrier function, reducing intestinal permeability, and modulating the gut environment.
- Other names
- L. salivarius BP121
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)IS (Indoxyl sulfate)OCLN (Occludin)TLR4 (Toll-like receptor 4)TJP1 (Tight junction protein 1 (ZO-1))
Beyond the preview
Go deeper on Lactobacillus salivarius BP121.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus salivarius BP121.